**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 79950

**Manuscript Type:** MINIREVIEWS

**Liver injury in COVID-19: A minireview**

Hu W *et al*. Liver injury in COVID-19

Wen-Shu Hu, Fang-Ying Jiang, Wen Shu, Rong Zhao, Ji-Min Cao, De-Ping Wang

**Wen-Shu Hu, Fang-Ying Jiang, Wen Shu, Rong Zhao, Ji-Min Cao,** Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China

**Wen-Shu Hu, Fang-Ying Jiang, Wen Shu, Rong Zhao, Ji-Min Cao, De-Ping Wang,** Department of Physiology, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China

**Author contributions:** Hu WS and Jiang FY contributed equally to this work; Hu WS, Jiang FY, Shu W, and Zhao R reviewed prior publications and drafted the manuscript; Cao JM and Wang DP revised the paper.

**Supported by** the Key Medical Science and Technology Program of Shanxi Province, No. 2020XM01; Shanxi “1331” Project Quality and Efficiency Improvement Plan, No. 1331KFC; Applied Basic Research Program of Shanxi Province, No. 202103021224234; and National Natural Science Foundation of China, No. 82170523.

**Corresponding author: De-Ping Wang, PhD, Lecturer,** Department of Physiology, Shanxi Medical University, No. 56 Xinjian Nan Road, Taiyuan 030001, Shanxi Province, China. wangdeping@sxmu.edu.cn

**Received:** September 12, 2022

**Revised:** November 2, 2022

**Accepted:** November 22, 2022

**Published online:**

**Abstract**

Coronavirus disease 2019 (COVID-19), caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has escalated into a global tragedy afflicting human health, life, and social governance. Through the increasing depth of research and a better understanding of this disease, it has been ascertained that, in addition to the lungs, SARS-CoV-2 can also induce injuries to other organs including the liver. Liver injury is a common clinical manifestation of COVID-19, particularly in severe cases, and is often associated with a poorer prognosis and higher severity of COVID-19. This review focuses on the general existing information on liver injury caused by COVID-19, including risk factors and subpopulations of liver injury in COVID-19, the association between preexisting liver diseases and the severity of COVID-19, and the potential mechanisms by which SARS-CoV-2 affects the liver. This review may provide some useful information for the development of therapeutic and preventive strategies for COVID-19-associated liver injury.

**Key Words:** Liver; SARS-CoV-2; Angiotensin-converting enzyme 2; Transmembrane serine protease 2; Chronic liver disease

Hu WS, Jiang FY, Shu W, Zhao R, Cao JM, Wang DP. Liver injury in COVID-19: A minireview. *World J Gastroenterol* 2022; In press

**Core Tip:** The global pandemic of coronavirus disease 2019 (COVID-19) has imposed a great threat to human health and become a medical and social challenge. Although severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mainly affects the respiratory tract, it also frequently damages the liver especially in severe and critical cases. Direct hepatotoxicity of SARS-CoV-2, or indirect hepatic injury caused by immune overactivation and systemic inflammation, drug-induced injury, ischemia/reperfusion and hypoxia/reoxygenation injuries, and worsening of preexisting liver diseases, are potential contributing factors to liver damage in COVID-19.

**INTRODUCTION**

In December 2019, an outbreak of the novel coronavirus disease 2019 (COVID-19) was reported in Wuhan, Hubei Province, China, induced by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 has evolved into a global health challenge[1], posing an enormous threat to human health and economic development. Severe COVID-19 patients may present symptoms of acute respiratory distress syndrome (ARDS), requiring admission to the intensive care unit (ICU) and oxygen ventilation therapy. The shortest time from admission to ARDS is approximately 2 d. At this stage, COVID-19 mortality is extremely high[2]. Global SARS-CoV-2 infection is now widespread, with 601189435 confirmed COVID-19 cases, including 6475346 deaths reported until September 3, 2022 by the WHO[3]. Most COVID-19 patients exhibit mild symptoms (fever, cough, shortness of breath, fatigue, vomiting, diarrhea, anosmia, and headache), whereas critical cases may develop into severe illness and even death due to severe lung injury and respiratory failure, liver injury, cardiac injury, septic shock, and even multi-organ failure[4].

Although COVID-19 mainly affects the respiratory tract, researchers have focused on the impacts of SARS-CoV-2 on other organs[5]. Liver injury is common in COVID-19 and is associated with poor prognoses. Liver test abnormalities, including higher levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are frequently observed in severe and critical COVID-19 cases compared to mild and moderate cases[6]. The most common manifestation of liver injury in COVID-19 is acute hepatitis with elevated AST, ALT, and total bilirubin levels[7]. Moderate microvascular steatosis and slight lobular activity are commonly observed in the liver biopsies[8]. Possible mechanisms include direct SARS-CoV-2 infection in hepatocytes or bile duct epithelial cells, excessive inflammation, drug-induced liver injury (DILI), ischemia/reperfusion syndrome, and liver injury associated with preexisting liver disease. Angiotensin-converting enzyme 2 (ACE2) is known to be the most important receptor for SARS-CoV-2 in contact with the host cell membrane, while transmembrane serine protease 2 (TMPRSS2) also plays an essential role in mediating viral entry. TMPRSS2 can prime the spike protein (S protein), and has been considered as a target for designing TMPRSS2 inhibitors to block virus entry as a new therapeutic approach[9]. When cells are infected by SARS-CoV-2, the S protein of the viral particles must be cleaved by TMPRSS2 and then binds to ACE2, so that viral particles can fuse with the plasma membrane and enter host cells[10]. Lower ACE2 expression has been detected in hepatocytes, while biliary epithelial cells express abundant ACE2 and thus can serve as a binding site for SARS-CoV-2. It has also been shown that most viruses that infect the respiratory tract can damage hepatocytes by affecting the CD8+ mediated immune response[11]. Common risk factors, such as older age, male sex, and a range of potential comorbidities, including hypertension, obesity, diabetes, and underlying liver diseases, can also lead to varying degrees of liver damage, critical illness, and even death. However, the exact connection between comorbidities and liver injury caused by SARS-CoV-2 remains unclear. This review summarizes the pathophysiology, possible mechanisms, clinical manifestations, risk factors, and special populations of liver injury in COVID-19 patients.

**PATHOPHYSIOLOGY OF LIVER INJURY IN COVID-19**

The mechanism of liver injury in COVID-19 remains largely unknown. SARS-CoV-2 may induce direct hepatotoxicity after entering into the liver *via* bile duct cells which express high levels of the ACE2 receptor. SARS-CoV-2 may also indirectly injure the liver *via* immune overactivation, systemic inflammation, drug toxicity, and hepatic hypoxia/reoxygenation or ischemia/reperfusion due to respiratory failure and endothelial damage (Figure 1). The liver is the main organ for detoxification and metabolism, and liver injury can reflect the severity and clinical course of COVID-19. Therefore, it is crucial to understand the mechanisms underlying liver injury in COVID-19 to develop effective treatments.

***Direct effect of SARS-CoV-2 on the liver***

Previous research has established that the ACE2 receptor can specifically bind to the S protein, which has a receptor binding domain (RBD) to mediate SARS-CoV-2 entry into host cells. Although the binding pattern of the SARS-CoV-2 RBD-ACE2 complex is greatly analogous to that of the SARS-CoV RBD-ACE2 complex, ACE2 has a higher affinity for the RBD of SARS-CoV-2[12]. This may be one possible reason why the SARS-CoV-2 is more dangerous than the other emerging SARS-CoVs. However, the level of ACE2 in the liver tissue is much lower than that in the bile duct based on previous data analysis, which suggests that SARS-CoV-2 may bind to ACE2-positive bile duct cells, but not hepatocytes[13]. Another possibility is that ACE2 can sense viral entry and upregulate its expression in hepatocytes[14]. Current evidence indicates that bile duct cells are actively involved in immune defense, inflammatory response, and liver regeneration, which may be a possible explanation for virus-induced liver injury once these cells are damaged. Cholangiocytes can co-express ACE2 and TMPRSS2, and are susceptible to viral infections[13]. Elevated levels of gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) are caused by bile duct cell injury[15]. A previous study reported the histological, ultrastructural, and immunohistochemical staining of liver biopsies performed on two patients who died of COVID-19. The researchers discovered a mass of viral particles of SARS-CoV-2 in the hepatocyte cytoplasm, and most of the viral particles had an intact coronoid envelope, indicating that SARS-CoV-2 can not only enter, but also replicate in the hepatocytes[14]. Another report also presented detailed liver histological results from two patients with acute COVID-19, and found extensive mitosis especially in the cholangiocytes, in addition to mixed inflammatory infiltrates in the portal region, endodermatitis, and severe bile duct injury[16]. Another study of three patient cohorts provided evidence of SARS-CoV-2 liver tropism. In autopsy reports from the third cohort of patients, viral RNA was detected in 69% of autopsy liver specimens and SARS-CoV-2 carrying infectiousness was detected in post-mortem liver tissues[17]. Regardless of whether SARS-CoV-2 directly affects cholangiocytes or hepatocytes, all the above studies support that the liver injury caused by SARS-CoV-2 is a direct cytopathic injury[16] (Figure 2A). Furthermore, obvious mitochondrial swelling, endoplasmic reticulum dilatation, and impaired cell membranes were also observed in two COVID-19 cases, suggesting cytopathic damage. However, pathological changes including moderate microvascular steatosis and slight lobular and portal inflammatory infiltration are non-specific in viral infection and can be caused by DILI or chronic liver disease (CLD) such as non-alcoholic fatty liver disease (NAFLD)[18]. In addition, no viral inclusion bodies were observed in the liver tissue of COVID-19 patients. In summary, it is still unclear whether SARS-CoV-2 directly causes cytopathic changes in liver cells.

***Systemic inflammatory response and cytokine storm in COVID-19***

Severe COVID-19 is characterized by a systemic inflammatory response that may cause a cytokine storm leading to multi-organ failure. Current evidence has shown that serum inflammatory cytokine levels are positively correlated with the indicators of liver dysfunction in COVID-19 patients[19]. This suggests that systemic inflammatory response and cytokine storm are also involved in liver injury, with a possible underlying mechanism between them. A previous study has shown that the activation and dysregulation of CD8+ T cells in severe patients may be an important factor for the pathogenesis of SARS-CoV-2 infection, as CD8+ T cells in critically ill patients express high levels of cytotoxic molecules[20]. A cohort study of 133 COVID-19 patients with liver damage reported high levels of inflammatory cytokines [TNF-α, interleukin (IL)-2, IL-6, and IL-10] and low levels of T lymphocyte subsets (CD3+, CD4+, and CD8+ T cells). IL-2, IL-6, IL-10, CD4+, and CD8+ T cells can be regarded as possible independent predictors of hepatic injury in COVID-19 patients[21]. This is consistent with an alternative study, which also revealed that the elevated levels of IL-2, IL-6, and IL-10 in the serum of COVID-19 patients were associated with the progression of severe disease[22]. Notably, IL-6 is particularly important for liver injury, because IL-6-mediated procoagulant endotheliopathy with increased hepatic von Willebrand factor (vWF) expression and platelet accumulation are linked to liver injury and liver inflammation (elevated ALT and neutrophil infiltration). In addition, IL-6 plays a potential role in hepatic endothelial dysfunction and inflammation because its level is correlated with vWF level[23]. IL-6 is associated with elevated liver enzymes, but the relationship is not necessarily causal, as IL-6 can be used to accurately detect inflammatory responses to liver injury[24]. IL-6 is activated primarily by the pathway of JAK (Janus kinase)/STAT (signal transducer and activator of transcription). Baricitinib, an inhibitor of the JAK/STAT pathway, can improve the clinical outcomes of COVID-19[25]. JAK inhibition can affect the viral entry and inflammation of COVID-19[26]. Previous studies have established an association between increased levels of endotoxin, ILs, and TNF-α in COVID-19 patients with liver function damage compared with those with normal liver function[27]. COVID-19 patients with elevated ALT levels also have increased IL-6, ferritin, lactate dehydrogenase (LDH), and C-reactive protein (CRP)[14]. Furthermore, significantly increased levels of IL-2, IL-7, IL-10, granulocyte colony-stimulating factor (G-CSF), and IP-10 (interferon-inducible protein-10) have been observed in severe patients compared with mild or moderate patients[22]. In conclusion, patients with severe COVID-19 may exhibit intense inflammation and cytokine storm syndrome leading to liver injury.

***DILI in COVID-19***

An additional opinion is that liver injury in COVID-19 patients is related to hepatotoxicity. DILI cannot be overlooked, as it may contribute to abnormal liver function, such as elevated ALT and ALP levels, and subsequently affect drug metabolism and excretion[28]. In addition, histopathologic findings from liver biopsies of COVID-19 patients, such as microvascular steatosis and liver inflammation, may also be associated with DILI[18]. Recent evidence suggests that DILI may occur secondarily to the drugs commonly used for COVID-19 treatment, such as paracetamol, antiviral therapies, low molecular weight heparin, anti-IL-6 receptor agents, and antibiotic treatments[29]. This is consistent with another study, in which corticosteroids and immune modulators were also mentioned[18]. Notably, NAFLD patients are more likely to develop DILI, because NAFLD can increase the sensitivity of the liver to hepatotoxicants, such as acetaminophen[30]. Antibiotics and nonsteroidal anti-inflammatory drugs are considered one of the most common causes of DILI[31]. One previous study showed that, when receiving glucocorticoid therapy, more patients had a liver injury (58.1%) than those without (39%)[32], and, tocilizumab (TCZ)-induced liver injury was reported in one COVID-19 patient. TCZ, also known as an IL-6 inhibitor, is recommended for the treatment of COVID-19 due to its vital role in inducing cytokines, and increased IL-6 can predict the fatal outcome of COVID-19. In this case, when TCZ was administrated, serum aminotransferase levels increased by nearly 40-fold on the first day, and after 10 d of DILI formation, aminotransferase levels returned to normal. Therefore, it is no doubt that TCZ has positive effects on other clinical and laboratory parameters of cytokine storm, such as CRP, IL-6, fibrinogen, and D-dimer, resulting in transaminase levels close to the normal range[33]. In brief, it is necessary to emphasize the importance of drug-related liver damage in patients with COVID-19, especially in those with underlying liver diseases.

***Hypoxia/reoxygenation and ischemia/reperfusion-induced liver damage***

COVID-19 is primarily characterized by respiratory failure, thus, severe cases of hypoxic hepatitis are commonly seen, and 10% of the cases suffer from a hypoxic liver injury in the ICU[34]. Hypoxic hepatitis, also known as ischemic hepatitis or shock liver[35], is accompanied by a rapid elevation of aminotransferases in cases of respiratory failure, shock, or heart failure. One possible reason is that the complex vascularization of the liver makes it susceptible to changes in circulation, resulting in decreased liver perfusion[31]. It has been shown that SARS-CoV-2 also causes liver damage by producing diffuse endodermatitis. Viral inclusion structures can also be observed in endothelial cells. Liver ischemia/reperfusion, including ischemia-induced cell injury and reperfusion-induced inflammatory responses resulting from the activation of neutrophils, Kupffer cells, and platelets, can induce the generation of reactive oxygen species (ROS) and calcium overload. Endothelial cells are involved in liver ischemia/reperfusion damage, which can promote oxidative stress through ROS and derivatives of nitric oxide[18]. ROS and lipid peroxidation products can mediate the production of redox-sensitive transcription factors, which in turn induce the release of abundant pro-inflammatory factors, resulting in hepatic injury[31]. Furthermore, hepatic sinusoidal endothelial cell damage has been reported to further aggravate hepatic ischemia and hypoxia by disturbing microcirculation[36]. In addition, a high level of positive end-expiratory pressure may be a possible contributor to liver injury in COVID-19 patients, because it can increase right atrial pressure and obstruct venous return, leading to hepatic stasis[37]. These findings indicate that hepatic hypoxia/reoxygenation and ischemia/reperfusion may be potential etiologies of COVID-19-related liver injury.

***The ACE2-independent pathway of liver injury***

In addition to receptor-mediated viral entry, antibody dependent enhancement (ADE) may also partially associated with hepatic injury in COVID-19 patients. ADE is a pathway that can enhance the interaction of virus-based antibodies, and the CR and/or FC receptor complements allow the virus to easily come into contact with macrophages, granulocytes, and monocytes. This results in the virus multiplying and increasing production, causing the infection to worsen. It has been identified that ADE can be activated by SARS-CoV antibodies, thus, SARS-CoV can trigger ADE activity in immune cells, even though the immune cells do not express ACE receptors (Figure 2B). However, there is a lack of discussion concerning the ADE pathway of liver injury, thus the ACE2-independent mechanisms of liver damage in COVID-19 remain unclear and warrant further study[27].

There is alternative hypothesis that liver cells express two receptors, CD147 and L-SIGN, which have an affinity for the S protein of SARS-CoV-2, and thus may mediate the infection of liver cells by SARS-CoV-2. The presence of CD147 on the surface of host cells may be a new way for SARS-CoV-2 invasion[38]. It has been experimentally verified that CD147 directly interacts with SARS-CoV-2 and that blocking CD147 can prevent SARS-CoV-2 replication, whereas massive expression of CD147 can promote SARS-CoV-2 replication[39]. These findings suggest that CD147 mediates the entry of SARS-CoV-2 into liver cells. However, this requires further exploration (Figure 2C). Additionally, L-SIGN serves as a liver-specific membrane receptor associated with viral capture. Autopsy studies have shown that L-SIGN receptors were present in SARS-CoV-2-infected sinusoidal cells[40] (Figure 2D). Therefore, L-SIGN may provide an alternative way for SARS-CoV-2 to invade the liver tissue.

***Clinical manifestation of liver injury in COVID-19***

Liver injury is common in severe COVID-19 cases, as shown by significant circulatory elevations in hepatocyte enzymes including ALT and AST, and a slight increase in cholangiocyte-related enzymes such as GGT and ALP. Mao *et al*[41] analyzed 35 studies involving 6686 COVID-19 patients, among which one in five patients developed liver function abnormalities, especially in severe cases. Therefore, paying close attention to liver function in COVID-19 patients before and during admission is necessary to control the severity of COVID-19. The main findings of the liver biopsy were moderate microvascular steatosis and mild lobular and portal activity. Other specific clinical manifestations of liver injury warrant further investigation.

***Abnormal liver function tests***

Liver test abnormalities are frequent in COVID-19 patients and often progress to severe illness. Liver function tests include hepatocyte injury markers ALT and AST, cholestasis or bile duct injury markers GGT and ALP, and measures of synthetic capacity [prothrombin time (PT) and albumin (ALB)]. One comprehensive study has described the results of liver tests from 417 patients with COVID-19 and found elevated levels of ALT and GGT (24%), AST and total bilirubin (TBIL, 12% and 15%), and no increase in ALP[42]. Such elevated GGT and normal ALP cannot be attributed to bile duct type but are possibly drug-induced liver injuries. GGT elevation is also considered to be a marker of substitution of excessive oxidative stress and increased inflammation due to acute inflammatory stress. However, by analyzing a small subset of COVID-19 patients with possible persistent abnormalities over 60 d, one study found that the predominant abnormality was a cholestatic pattern, as indicated by elevation of the ALP/GGT ratio[43]. Although GGT is not a specific marker of liver injury, liver damage may result from direct bile duct cell injury and cholestasis induced by SARS-CoV-2[43]. Many studies in China revealed that COVID-19 patients who used lopinavir/ritonavir during hospitalization had liver injuries that influenced liver tests[44]. A cohort study including 1040 COVID-19 patients (mean age 38 years old, 54% men) revealed that drugs used for treatment, such as lopinavir-ritonavir, interferon beta, and/or corticosteroids, are correlated with an elevation in the ALT/AST ratio, which acts as an independent contributor to worse clinical outcomes[45]. Using a random effect method and an inverse variance approach, a meta-analysis was conducted using 128 studies, identifying that the most common abnormalities were hypoalbuminemia [61.27% (48.24-72.87)], increased levels of GGT [27.94% (18.22-40.27)], ALT [23.28% (19.92-27.01)] and AST [23.41% (18.84-28.70)][46]. Notably, hypoalbuminemia is an independent risk predictor of liver dysfunction and mortality upon admission[47]. One previous study analyzed 2623 confirmed COVID-19 cases at different risk levels, including non-critically ill, critically ill, and deceased groups[48]. This study revealed that hypoalbuminemia may be due to hepatotoxicity of the cytokine storm. In addition, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels were significantly lower in the critically ill and dead groups than in the non-critically ill group. Furthermore, patients with abnormal liver function had higher inflammatory indices, such as a high level of CRP which is associated with disease severity. Patients with an increased level of ALP have significantly elevated CRP levels, and CRP levels are correlated with ALT levels[49]. Notably, D-dimer, LDH, creatine kinase, and troponin levels are also higher in patients with abnormal liver function tests than in those with normal liver function[50]. A retrospective study analyzed 216 patients diagnosed with COVID-19 and concluded that elevated LDH is an independent contributing factor to ICU admission and may require mechanical ventilation[51]. However, the increase in serum LDH does not specifically reflect cellular damage in the liver, because LDH is present in many organs.

In summary, abnormal liver function tests are frequent in COVID-19 patients, which are secondary to other injuries, mostly ischemia or drug-induced liver damage. Patients with abnormal liver tests have extended hospital stay and are at higher risk of developing severe disease; however, this does not directly leading to death[52].

***Hepatic histopathological findings in COVID-19***

Hepatic histopathological findings in patients who died from COVID-19 revealed moderate microvascular steatosis in addition to mild lobular and portal activity. This is consistent with other studies suggesting that the changes are non-specific, and liver injury may be due to SARS-Cov-2 or drugs, but not caused by cholestasis[8,53,54]. Some studies have found sinusoidal thrombosis, which is less common and is mostly observed in severe COVID-19, because COVID-19 is a prothrombotic disease[55,56]. A case study of the liver autopsy of an elderly patient with COVID-19 found no obvious inflammation in the portal area, but observed a few hepatocytes with slight vesicular steatosis and watery degeneration, possibly associated with ischemia and hypoxia[42]. Inflammatory cells, including neutrophils, plasma cells, and Kupffer cells, were observed in the hepatic sinuses at a higher magnification. In addition, numerous scattered or apoptotic hepatocytes characterized by nuclear condensation or formation of apoptotic bodies were also observed in liver biopsy tissues, but no viral inclusions were observed[14], similar to the results of Wang *et al*[32]. Based on these studies, direct effect of SARS-CoV-2 on hepatocytes seems less convincing. Notably, a report on the histopathological findings of 40 patients who died from COVID-19 revealed that mild lobular necroinflammation was present in 20 (50%) cases, with few infiltrations of lymphocytes and histiocytes[55]. Hepatocyte degeneration with focal necrosis and low infiltrations of leukocytes in the lobular and portal areas have also been observed in an alternative liver biopsy study of deceased COVID-19 patients[57]. Liver biopsies from three patients and necropsies from three others revealed striking iron accumulation in hepatocytes, and an abundance of ferritin particles in damaged mitochondria[58], suggesting that hepatic iron overload could have a potential relationship with liver injury. Post-mortem wedge liver tissues from 48 deceased COVID-19 patients suggest that different degrees of liver injuries are present, including liver blood involvement and acute (thrombosis and lumen expansion ) and chronic (fibrous thickening of vessel wall and portal vein fibrosis) liver injuries[59]. In conclusion, the most common seen liver histopathological findings were hepatic steatosis, portal inflammation, and varying degrees of liver injury. However, related investigations into the mechanisms and etiologies of hepatic histopathological changes are still lacking.

***Other special clinical manifestations***

In addition to the elevated liver enzymes and histopathologic changes described above, other specific manifestations of liver damage in COVID-19 patients have also been reported, including a darkened face and pigmentation. Pigmentation may be a result of abnormal liver metabolism *via* the following mechanisms. First, liver dysfunction can increase estrogen levels, thereby damaging the inhibitory effect of thiamine on tyrosinase, so that more tyrosine is transformed into melanin. Second, abnormal liver function may result in hypofunction of adrenocortical hormones, and melanin secretion is increased due to the elevation of the melanocyte-stimulating hormone. In addition, more iron may enter into the blood vessels due to liver damage, increasing the ion level in the blood circulation to the facial skin and resulting in a darkened face[27].

**COVID-19-INDUCED LIVER INJURY IN SPECIAL POPULATIONS**

***Risk factors of severe COVID-19 and liver injury***

A growing body of studies suggests that male sex, older age, and potential comorbidities, such as hypertension, obesity, diabetes, cardiovascular diseases, and respiratory diseases, and particularly obesity and type 2 diabetes, are more likely to be associated with critical COVID-19 after infection by SARS-CoV-2[60]. One study involving 174 consecutive COVID-19 patients shows that 24 of them had no other comorbidities but diabetes. By comparing the diabetic group with the non-diabetic group, it was found that COVID-19 patients with diabetes more easily experienced an overactivated inflammatory response and a hypercoagulable state, resulting in a worse COVID-19. The mechanism could be that COVID-19 patients with diabetes are easy to develop inflammatory storm that rapidly worsens COVID-19 due to high blood levels of inflammatory factors, such as IL-6, CRP, serum ferritin, coagulation index, and D-dimer[61]. These proinflammatory cytokines were strongly correlated with liver injury, so it is worth paying attention to whether patients with a history of diabetes are more susceptible to liver injury. Age is by far the most associated risk factor of COVID-19, with the risk increasing gradually after 65 years[62]. This may be due to T cell and B cell functions which show age-dependent defects, as well as inadequate control of viral replication due to overproduction of type 2 cytokines and prolonged inflammatory responses[63]. Compared to infected adults, infected children usually present with mild clinical symptoms, and are mostly asymptomatic[64]. This may be because of their immature immune systems. Past reports have confirmed that children with abnormal liver function tests such as increased ALT usually have a preexisting condition such as an immunocompromised state (including malignancy) or CLD[65]. Patients with poor underlying liver conditions, such as cirrhosis, hyperplasia, non-alcoholic steatohepatitis, and mild steatosis, could have high expression of ACE2 than those without liver diseases[66]. Preexisting liver disease and age ≥ 60 years are risk factors for progressing to severe COVID-19[67]. Besides, male sex is linked to the severity of COVID-19 and has been identified as an important etiology of liver injury, possibly due to the lack of the protective effect of estrogen on the liver[68], or the enhancement of male innate immunity and the activation of T cells[62].

Notably, patients with obesity represent a dysregulated hepatic innate immunity, adaptive immune response, and pro-inflammatory state, thus aggravating the cytokine storm caused by SARS-CoV-2 infection, resulting in worse prognoses of COVID-19[60]. To evaluate the relationship between obesity and COVID-19, a meta-analysis was conducted using 50 studies in total with a total of 18260378 eligible subjects. It was found that obesity increased the chance of contracting SARS-CoV-2 and developing critical COVID-19. In addition, patients with a body mass index (BMI) ≥ 30 were 1.39 times more susceptible to SARS-CoV-2 infection compared with those with normal body weight, and the hospitalization rate of COVID-19 became higher with increasing BMI[69]. However, fatty liver is not a predisposing factor for hepatic injury after SARS-CoV-2 infection compared with the susceptibility rate of the general population[70].

In addition to the above risk factors, chronic heart disease, excessive inflammatory response, extended prothrombin time (PT), elevated liver enzymes, and high levels of bilirubin may also be related to severe COVID-19 and mortality[71]. In conclusion, the sex of the patient (males), older age, and comorbidities were independent risk factors for the rapid aggravation of COVID-19. Patients older than 60 years with a history of diabetes have an increased risk of mortality[72]. However, the exact association between liver injury and risk factors remains unclear.

***Preexisting liver diseases and severity of COVID-19***

CLD is deemed to be a major burden of disease and a threat to human worldwide. CLD mainly includes cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease, and chronic hepatitis B, which affects nearly 300 million people in China. Because of this high burden, it is necessary to carefully assess the relationship between underlying liver disease and liver injury in patients with COVID-19[73]. However, the extent to which CLD affects the liver function and the disease ending in COVID-19 is controversial. On the one hand, patients with CLD are thought to be more susceptible to viral infection and developing liver injury due to an altered immune status. On the other hand, previous studies reveal that CLD is rarely related to the progression of liver injury or critical/fatal outcomes of COVID-19 (Table 1)[74]. Therefore, the connection between the underlying liver disease and COVID-19 requires further investigation.

***Cirrhosis and COVID-19***

Cirrhotic patients have complex immune disorders and are more susceptible to infection, and the leading causes of mortality are not only respiratory complications but also deterioration of liver function, leading to end-stage liver disease. Patients with cirrhosis are not only at risk of related immune dysfunction, but also are more likely to have comorbidities that predispose them to severe COVID-19, such as diabetes, chronic kidney disease, and heart disease[75]. However, there is a debate about the risk of cirrhosis on the clinical outcomes of COVID-19. A multicenter retrospective study revealed that cirrhotic patients infected with COVID-19 have a high 30-d mortality rate[76]. In this study, elevated transaminases may have had an adverse influence on the process of cirrhosis, and ALT levels in cirrhotic patients were affected by SARS-CoV-2. Additionally, nearly half of the patients who previously had normal transaminases developed to an acute liver injury. Indeed, patients with impaired liver function have a higher 30-d mortality rate and more studies suggested that cirrhotic patients are more susceptible to infection resulting from immune dysfunction. SARS-CoV-2 damages the lymphocytes, especially T cells, resulting in impaired immune function and increased sensitivity to the viruses. Moreover, an elevated neutrophil-to-lymphocyte ratio (NLR) increases the risk of bacterial infection, which is related to stress and sepsis, particularly in decompensated liver cirrhosis leading to a worse outcome[67]. In a study of 386 patients with cirrhosis, 32% had a growing risk of mortality after SARS-CoV-2 infection. Patients with CLD without cirrhosis just have a similar risk of mortality as patients without liver disease[77]. In addition, cirrhotic patients with SARS-CoV-2 infection appear to have a high risk of developing acute hepatic decompensation (46%), as well as a 2-fold increased rate of mortality. These studies suggest that cirrhosis is closely linked to the disease progression from COVID-19.

Contrary opinions argue that CLD and cirrhosis have little correlation with the critical and mortality rates of COVID-19. One study found that there was no increase in liver damage after SARS-CoV-2 infection in CLD patients[18]. However, the results may be relatively low persuasive, because only three patients with cirrhosis were studied.

***Hepatitis B and COVID-19***

Recent evidence suggests that liver injury in patients co-infected with SARS-CoV-2 and hepatitis B virus (HBV) leads to increased disease severity and worse clinical outcomes[78]. In addition, liver test abnormalities often appear in patients co-infected with SARS-CoV-2 and HBV, with elevated levels of ALT, AST, ALP, and TBIL.

In addition, the largest multicenter retrospective study revealed several novel risk factors such as high levels of LDH, D-dimer, and reduced ALB or ALB/globulin (GLO), which increase the risk of COVID-19 severity and mortality in patients with chronic hepatitis B (CHB)[79]. An alternative study showed similar results: High levels of LDH, D-dimer, and IL-6 were more likely to worsen liver function in COVID-19 patients following HBV coinfection. Two weeks after the onset of symptoms, serum LDH levels were increased only in patients with COVID-19 and HBV coinfection compared with patients without HBV coinfection[80]. The conditions of four chronic HBV-infected patients were further aggravated after SARS-CoV-2 coinfection, as presented by progressive jaundice elevation, coagulation disorders, and ascites, and developed acute-on-chronic liver failure[78]. These findings suggest that SARS-CoV-2 and HBV coinfection is related to disease severity and poor clinical presentation, and affects liver function tests and that HBV inactive carriers have more severe liver damage. This may be due to the altered immune status caused by SARS-CoV-2 coinfection. Other possible reasons include inactive HBV carriers, who are more prone to HBV reactivation and liver injury with ALT flares caused by SARS-CoV-2 coinfection, and these patients have increased sensitivity to hepatotoxic antiviral drugs used for COVID-19 treatment[80].

There are opposing opinions that chronic HBV coinfection is not a predictive factor for the disease severity or poor prognosis of COVID-19. A study using a prognostic model with a nomogram indicated that HBV infection was not linked to the mortality risk of COVID-19[81]. Several studies have supported this hypothesis. A cohort study of 326 confirmed COVID-19 patients shows that 20 (6.1%) had HBV coinfection, and the outcomes of the 20 patients (including rates of severe/critically ill, mortality, and discharged and hospital stays) showed no difference from those of patients without coinfection, and HBV coinfection did not increase the degree of liver injury[82]. This is consistent with the results of a previous review indicating that the degree of hepatic damage in patients with HBV and SARS-CoV-2 coinfection is not significantly different from that in patients with SARS-CoV-2 infection alone[83]. Therefore, whether or not HBV infection affects the clinical manifestations and outcomes of COVID-19, and how, requires further study.

***Metabolic dysfunction-associated fatty liver disease and COVID-19***

Metabolic dysfunction-associated fatty liver disease (MAFLD), previously defined as NAFLD, has been reported to be associated with increased ICU admissions and the need for mechanical ventilation after infection with SARS-CoV-2. However, it was not a predictive factor for death in COVID-19[18]. MAFLD is the most frequently occurring chronic disease in the world, with a common incidence of 30%, and is regarded as a liver performance of the metabolic syndrome. There is a distinct lack of research regarding the history of liver disease in COVID-19 patients and the connection between MAFLD and COVID-19[84]. A meta-analysis of COVID-19 comorbidities showed upregulation of ACE2 receptor expression in NAFLD[85]. A cohort study of 202 consecutive COVID-19 patients showed that patients with NAFLD had prolonged virus-shedding time and increased risk of disease severity compared to non-NAFLD patients[86]. In addition, a previous study has shown that younger patients (age < 60 years) with MAFLD have increased disease severity, possibly due to the higher incidence of cytokine storm caused by MAFLD in younger patients[87]. This is consistent with an alternative multicenter study that compared the risks of developing severe COVID-19 between younger and older patients with MAFLD. Results showed that 55.9% of the younger and 24% of the elderly developed severe COVID-19 (*P* = 0.01)[88], suggesting that younger MAFLD patients have an higher risk of developing severe COVID-19, while MAFLD in older patients appears to have little association with disease severity.

The mechanism underlying age-related disease severity in COVID-19 remains unclear. Possible explanations include: (1) Younger MAFLD patients are more likely to exhibit liver and systemic immune responses, and thereby a cytokine storm after SARS-CoV-2 infection; (2) older MAFLD patients usually have a higher burden of comorbidities which may harm COVID-19 and mask the link between MAFLD and COVID-19 severity[88]; (3) cytokine storm has been shown to increase in obese patients, especially in those with preexisting MAFLD[89]; (4) BMI is much higher in patients with NAFLD than in those without[90]; (5) MAFLD is also linked to abnormal levels of aminotransferases and GGT[89]; and (6) the connection between MAFLD and the severity of COVID-19 may be related to the release of pro-inflammatory mediators, such as, tumor necrosis factor-alpha and IL-6[91]. Notably, one study reported that the prognosis of MAFLD is closely related to the degree of fibrosis, and thus could affect the outcomes of COVID-19[63]. When MAFLD is accompanied by severe advanced liver fibrosis, it may exacerbate the cytokine storm caused by the virus, thus the release of proinflammatory cytokines leads to more severe COVID-19. In conclusion, unhealthy lifestyles contribute to the high morbidity of MAFLD and high risk of severe COVID-19.

***Alcoholic liver disease and COVID-19***

A previous study revealed an unprecedented increase in both ALD and liver transplant rates during the spread of COVID-19[92]. Therefore, more research focus should be placed on ALD, in relation to the COVID-19 pandemic. It was reported by the Centers for Disease Control and Prevention in the US that the mortality due to ALD has increased rapidly during the COVID-19 pandemic. One possible reason for this is the high consumption of alcohol and the increase in alcohol-related comorbidities before and during the COVID-19 pandemic. Other possible reasons include increased obesity/metabolic syndrome and NAFLD, which also contribute to the risk of ALD development. In addition, a study found that females and young adults showed the highest relative increases in ALD-related mortality, while older adults over the age of 85 years presented a smaller increase in overall female mortality and even a decrease in male mortality[93]. A comprehensive study of 978 CLD patients with SARS-CoV-2 infection from 21 institutions in the United States revealed a novel association between ALD and poor survival or COVID-19 related mortality. It has been confirmed that patients with preexisting ALD may be more susceptible to contracting COVID-19 due to immune system dysregulation. ALD is associated with a sterile inflammatory state caused by an injury-related molecular pattern, resulting in the spread of pro-inflammatory cytokines throughout the body. In addition, SARS-CoV-2-induced cytokine storm may exacerbate inflammation in patients with ALD, leading to worse clinical outcomes[94]. In a report on the trends in alcohol consumption and liver disease before and after COVID-19, more than a third of patients with CLD and 50% with ALD consumed alcohol daily, suggesting that high alcohol consumption may indicate a relationship with poor prognosis of COVID-19. There are many possible reasons why alcohol abuse leads to poor outcomes. Alcohol abuse and related liver disease can disrupt the innate and acquired immune systems due to impaired immune cell function and survival, which participate in defending against viral infections. Another reason may be that patients with chronic alcohol consumption are more likely to develop ARDS, thus leading to a worse outcome[95].

***Liver transplant and COVID-19***

Liver transplant recipients are more likely to develop severe COVID-19, due to chronic immunosuppression and related comorbidities, which may lead to mortality[96]. A systematic search of 15 studies consisting of 223 Liver transplant patients, among which 77.7% required hospitalization, found that 36% experienced more severe disease, with a higher mortality rate observed in the cohort compared with approximately 1%-4% in the general population. In addition, liver transplant recipients often present with fever and dyspnea which are similar to common COVID-19 manifestations; however, liver transplant recipients are more likely to have concurrent diarrhea symptoms. Furthermore, older liver transplant recipients (aged > 60 years) with diabetes are at an increased risk of mortality[72]. Another study compared 151 Liver transplant patients (68% male, median age of 60 years) with 627 non-transplanted patients (52% male, median age of 73 years), showing that groups of liver transplant patients tended to have ICU admission (28% *vs* 8%) and needed treatment with invasive ventilation (20% *vs* 5%), while mortality was lower in the liver transplant cohort than in the non-transplant cohort (19% *vs* 27%). Several statistical analyses have shown age-related mortality among liver transplant recipients[18]. Similarly, the first nationwide study compared the morbidity and outcomes of 111 Liver transplant patients infected with SARS-CoV-2 with those of the general population, matched for age and sex[97]. Liver transplant recipients have a doubled risk of developing COVID-19, but have a lower standardized mortality rate compared to the general population. They conclude that chronic immunosuppression and increased comorbidity make the liver transplant recipients more likely to suffer from the infection of the virus and develop to COVID-19, whereas chronic immunosuppression can resist the most severe forms of COVID-19 and play a protective role against the virus, resulting in reduced mortality rates.

**DISCUSSION**

COVID-19 caused by SARS-CoV-2 infection is a worldwide epidemic, which has had catastrophic impacts on healthcare systems and social management. Although SARS-CoV-2 mainly affects the respiratory tract, current studies have also focused on multi-organ injury particularly liver injury, with liver test abnormalities identified as an important extrapulmonary manifestation related to SARS-CoV-2 infection[98]. As liver dysfunction is associated with disease severity and poor clinical presentation, understanding the pathogenesis of liver injury and its associated risk factors is extremely important for the prognosis and treatment of the disease. This review briefly summarizes the onset, mechanism, risk factors, susceptible groups, and correlation between liver injury and the clinical outcomes of COVID-19.

According to previous studies, hypoalbuminemia and elevated AST and ALT levels are frequently observed in severe COVID-19 cases, indicating abnormal liver function. These elevations are usually accompanied by elevated LDH. GGT levels were also generally elevated, but ALP elevation was not evident in most studies. Although it is debated whether the pattern of liver injury is hepatocellular or cholestatic, the vast majority of studies support the hepatocellular injury. However, because of the high expression of ACE2 receptors in cholangiocytes, the hypothesis that liver injury results from the direct cytopathic effect of SARS-CoV-2 on hepatocytes seems unconvincing. Liver injuries likely reflect the severity of the disease. Liver histopathological studies predominantly showed moderate microvascular steatosis and slight lobular activity and inflammatory infiltration of the portal area in the biopsy and autopsy of COVID-19 cases. However, the exact mechanisms of liver injury in COVID-19 are still unclear, perhaps more cases are due to indirect liver injury.

Predisposing risk factors for liver damage in COVID-19 include male sex, older age, other comorbidities, and underlying CLDs. Men are more likely to develop liver injury than women because of the stronger innate immune system in men and estrogen protection in women. Patients aged > 65 years appear to exhibit a progressive increase in the risk of developing severe disease. Obesity is also a contributing factor to severe COVID-19, because dysregulated hepatic innate immunity, adaptive immune response, and pro-inflammatory state are usually present in fatty cases, which may aggravate the cytokine storms. Cytokine storms can be enhanced in patients with preexisting MAFLD. The contributions of other preexisting CLDs (including cirrhosis, ALD and chronic hepatitis B) to the progression of disease severity and liver injury in COVID-19 remain controversial. Most studies have emphasized that CLDs are more susceptible to severe COVID-19 due to immune disorders, and CLDs are often associated with abnormal liver function tests. However, CLD is not a predictor of mortality. Liver transplant recipients have many potential risk factors for developing worse outcomes in COVID-19, but it appears that chronic immunosuppression can protect COVID-19 patients from developing severe disease and thus reduce the mortality. Older liver transplant recipients (aged > 60 years) with diabetes are at increased risk of mortality. The exact link between CLD and COVID-19 is unclear, and whether CLD aggravates liver dysfunction and worsens the clinical outcomes of COVID-19 remains ambiguous.

**CONCLUSION**

Liver injury is frequent in patients with COVID-19 and abnormal liver function tests are more often observed in severe cases. Risk factors and populations for liver dysfunction in COVID-19 patients include male sex, older age, underlying comorbidities (particularly diabetes, hypertension, and obesity) and preexisting liver diseases (CLD and liver transplant). The mechanisms underlying liver injury in COVID-19 patients remain unclear, which are more likely due to the direct effect of the virus on hepatocytes or the biliary epithelium, and the indirect effects of excessive inflammation, drugs, and ischemia/hypoxia syndromes. Collectively, liver injury in COVID-19 patients is associated with increased disease severity and requires additional attention and effective treatments. In addition, targeted therapy is needed for patients with preexisting liver diseases, especially older patients with comorbidities. Further research is needed to determine whether the underlying disease coexists with COVID-19 to cause severe diseases that causes liver damage, or whether the underlying conditions directly contribute to liver damage. Attention should also be paid to DILI during the treatment of COVID-19, especially the conventional and new drugs used for specific groups. The information discussed in this review may aid in establishing recommendations and guidance for the treatment of liver injury in COVID-19 to reduce liver burden.

**REFERENCES**

1 **Li H**, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B. SARS-CoV-2 and viral sepsis: observations and hypotheses. *Lancet* 2020; **395**: 1517-1520 [PMID: 32311318 DOI: 10.1016/S0140-6736(20)30920-X]

2 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

3 **Andersen KG**, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. *Nat Med* 2020; **26**: 450-452 [PMID: 32284615 DOI: 10.1038/s41591-020-0820-9]

4 **Berlin DA**, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med* 2020; **383**: 2451-2460 [PMID: 32412710 DOI: 10.1056/NEJMcp2009575]

5 **Santana MF**, Guerra MT, Hundt MA, Ciarleglio MM, Pinto RAA, Dutra BG, Xavier MS, Lacerda MVG, Ferreira AJ, Wanderley DC, Borges do Nascimento IJ, Araújo RFA, Pinheiro SVB, Araújo SA, Leite MF, Ferreira LCL, Nathanson MH, Vieira Teixeira Vidigal P. Correlation Between Clinical and Pathological Findings of Liver Injury in 27 Patients With Lethal COVID-19 Infections in Brazil. *Hepatol Commun* 2022; **6**: 270-280 [PMID: 34520633 DOI: 10.1002/hep4.1820]

6 **Zhong P**, Xu J, Yang D, Shen Y, Wang L, Feng Y, Du C, Song Y, Wu C, Hu X, Sun Y. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. *Signal Transduct Target Ther* 2020; **5**: 256 [PMID: 33139693 DOI: 10.1038/s41392-020-00373-7]

7 **Osorio Martínez A**, González-Razo VT, Navarro-Sánchez V, Souto Meiriño CA, Ahumada-Ayala M. SARS-CoV-2-Related Subacute Thyroiditis, Myocarditis, and Hepatitis After Full Resolution of COVID-19 Serum Markers. *Am J Case Rep* 2021; **22**: e932321 [PMID: 34138828 DOI: 10.12659/AJCR.932321]

8 **Xu Z**, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420-422 [PMID: 32085846 DOI: 10.1016/S2213-2600(20)30076-X]

9 **Hoffmann M**, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**: 271-280.e8 [PMID: 32142651 DOI: 10.1016/j.cell.2020.02.052]

10 **Inde Z**, Croker BA, Yapp C, Joshi GN, Spetz J, Fraser C, Qin X, Xu L, Deskin B, Ghelfi E, Webb G, Carlin AF, Zhu YP, Leibel SL, Garretson AF, Clark AE, Duran JM, Pretorius V, Crotty-Alexander LE, Li C, Lee JC, Sodhi C, Hackam DJ, Sun X, Hata AN, Kobzik L, Miller J, Park JA, Brownfield D, Jia H, Sarosiek KA. Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity. *Sci Adv* 2021; **7** [PMID: 34407940 DOI: 10.1126/sciadv.abf8609]

11 **Bzeizi K**, Abdulla M, Mohammed N, Alqamish J, Jamshidi N, Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. *Sci Rep* 2021; **11**: 10599 [PMID: 34012016 DOI: 10.1038/s41598-021-89513-9]

12 **Wang MY**, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. *Front Cell Infect Microbiol* 2020; **10**: 587269 [PMID: 33324574 DOI: 10.3389/fcimb.2020.587269]

13 **Lui VC**, Hui KP, Babu RO, Yue H, Chung PH, Tam PK, Chan MC, Wong KK. Human liver organoid derived intra-hepatic bile duct cells support SARS-CoV-2 infection and replication. *Sci Rep* 2022; **12**: 5375 [PMID: 35354880 DOI: 10.1038/s41598-022-09306-6]

14 **Wang Y**, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, Cao Y, Kang J, Yang J, Li L, Liu X, Li Y, Nie R, Mu J, Lu F, Zhao S, Lu J, Zhao J. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol* 2020; **73**: 807-816 [PMID: 32437830 DOI: 10.1016/j.jhep.2020.05.002]

15 **Wu Y**, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. *Hepatol Int* 2020; **14**: 621-637 [PMID: 32710250 DOI: 10.1007/s12072-020-10074-6]

16 **Fiel MI**, El Jamal SM, Paniz-Mondolfi A, Gordon RE, Reidy J, Bandovic J, Advani R, Kilaru S, Pourmand K, Ward S, Thung SN, Schiano T. Findings of Hepatic Severe Acute Respiratory Syndrome Coronavirus-2 Infection. *Cell Mol Gastroenterol Hepatol* 2021; **11**: 763-770 [PMID: 32992052 DOI: 10.1016/j.jcmgh.2020.09.015]

17 **Wanner N**, Andrieux G, Badia-I-Mompel P, Edler C, Pfefferle S, Lindenmeyer MT, Schmidt-Lauber C, Czogalla J, Wong MN, Okabayashi Y, Braun F, Lütgehetmann M, Meister E, Lu S, Noriega MLM, Günther T, Grundhoff A, Fischer N, Bräuninger H, Lindner D, Westermann D, Haas F, Roedl K, Kluge S, Addo MM, Huber S, Lohse AW, Reiser J, Ondruschka B, Sperhake JP, Saez-Rodriguez J, Boerries M, Hayek SS, Aepfelbacher M, Scaturro P, Puelles VG, Huber TB. Molecular consequences of SARS-CoV-2 Liver tropism. *Nat Metab* 2022; **4**: 310-319 [PMID: 35347318 DOI: 10.1038/s42255-022-00552-6]

18 **Gracia-Ramos AE**, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. *World J Gastroenterol* 2021; **27**: 3951-3970 [PMID: 34326607 DOI: 10.3748/wjg.v27.i26.3951]

19 **Zhu DD**, Tan XM, Lu LQ, Yu SJ, Jian RL, Liang XF, Liao YX, Fan W, Barbier-Torres L, Yang A, Yang HP, Liu T. Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury. *World J Gastroenterol* 2021; **27**: 2944-2962 [PMID: 34168400 DOI: 10.3748/wjg.v27.i22.2944]

20 **Song JW**, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. Immunological and inflammatory profiles in mild and severe cases of COVID-19. *Nat Commun* 2020; **11**: 3410 [PMID: 32641700 DOI: 10.1038/s41467-020-17240-2]

21 **Liao S**, Zhan K, Gan L, Bai Y, Li J, Yuan G, Cai Y, Zhang A, He S, Mei Z. Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients. *Signal Transduct Target Ther* 2020; **5**: 255 [PMID: 33130825 DOI: 10.1038/s41392-020-00363-9]

22 **Gao Y**, Li Q, Shi H, Feng Y, Zhang T, Chen Y, Liang L, Chen D, Wu H, Jin R, Huang X. Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients. *Front Med (Lausanne)* 2020; **7**: 501 [PMID: 32903864 DOI: 10.3389/fmed.2020.00501]

23 **McConnell MJ**, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee AI, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. *J Hepatol* 2021; **75**: 647-658 [PMID: 33991637 DOI: 10.1016/j.jhep.2021.04.050]

24 **Da BL**, Kushner T, El Halabi M, Paka P, Khalid M, Uberoi A, Lee BT, Perumalswami PV, Rutledge SM, Schiano TD, Friedman SL, Saberi B. Liver Injury in Patients Hospitalized with Coronavirus Disease 2019 Correlates with Hyperinflammatory Response and Elevated Interleukin-6. *Hepatol Commun* 2021; **5**: 177-188 [PMID: 33230491 DOI: 10.1002/hep4.1631]

25 **Stebbing J**, Sánchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, Shen JX, Sommerauer C, Tiseo G, Ghiadoni L, Virdis A, Monzani F, Rizos LR, Forfori F, Avendaño Céspedes A, De Marco S, Carrozzi L, Lena F, Sánchez-Jurado PM, Lacerenza LG, Cesira N, Caldevilla Bernardo D, Perrella A, Niccoli L, Méndez LS, Matarrese D, Goletti D, Tan YJ, Monteil V, Dranitsaris G, Cantini F, Farcomeni A, Dutta S, Burley SK, Zhang H, Pistello M, Li W, Romero MM, Andrés Pretel F, Simón-Talero RS, García-Molina R, Kutter C, Felce JH, Nizami ZF, Miklosi AG, Penninger JM, Menichetti F, Mirazimi A, Abizanda P, Lauschke VM. JAK inhibition reduces SARS-CoV-2 Liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. *Sci Adv* 2021; **7** [PMID: 33187978 DOI: 10.1126/sciadv.abe4724]

26 **Mehta P**, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033-1034 [PMID: 32192578 DOI: 10.1016/S0140-6736(20)30628-0]

27 **Mohamed DZ**, Ghoneim ME, Abu-Risha SE, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. *World J Gastroenterol* 2021; **27**: 4504-4535 [PMID: 34366621 DOI: 10.3748/wjg.v27.i28.4504]

28 **Cao J**, Cai X, Chen M. Liver Injury in COVID-19: Caution and Management. *Liver Cancer* 2020; **9**: 625-626 [PMID: 33083285 DOI: 10.1159/000508696]

29 **Anirvan P**, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. *World J Hepatol* 2020; **12**: 1182-1197 [PMID: 33442447 DOI: 10.4254/wjh.v12.i12.1182]

30 **Boeckmans J**, Rodrigues RM, Demuyser T, Piérard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? *Arch Toxicol* 2020; **94**: 1367-1369 [PMID: 32266419 DOI: 10.1007/s00204-020-02734-1]

31 **D'Ardes D**, Boccatonda A, Cocco G, Fabiani S, Rossi I, Bucci M, Guagnano MT, Schiavone C, Cipollone F. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship. *World J Gastroenterol* 2022; **28**: 1102-1112 [PMID: 35431501 DOI: 10.3748/wjg.v28.i11.1102]

32 **Wang M**, Yan W, Qi W, Wu D, Zhu L, Li W, Wang X, Ma K, Ni M, Xu D, Wang H, Chen G, Yu H, Ding H, Xing M, Han M, Luo X, Chen T, Guo W, Xi D, Ning Q. Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. *Hepatol Int* 2020; **14**: 723-732 [PMID: 33026573 DOI: 10.1007/s12072-020-10075-5]

33 **Muhović D**, Bojović J, Bulatović A, Vukčević B, Ratković M, Lazović R, Smolović B. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. *Liver Int* 2020; **40**: 1901-1905 [PMID: 32478465 DOI: 10.1111/Liv.14516]

34 **Sun J**, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int* 2020; **40**: 1278-1281 [PMID: 32251539 DOI: 10.1111/Liv.14470]

35 **Roedl K**, Jarczak D, Drolz A, Wichmann D, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, Lütgehetmann M, Kluge S, Fuhrmann V. Severe liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect? *Ann Intensive Care* 2021; **11**: 44 [PMID: 33721137 DOI: 10.1186/s13613-021-00835-3]

36 **Cai Y**, Ye LP, Song YQ, Mao XL, Wang L, Jiang YZ, Que WT, Li SW. Liver injury in COVID-19: Detection, pathogenesis, and treatment. *World J Gastroenterol* 2021; **27**: 3022-3036 [PMID: 34168405 DOI: 10.3748/wjg.v27.i22.3022]

37 **Chen P**, Zhou B. Clinical Characteristics of COVID-19 in Patients With Liver Injury. *Clin Gastroenterol Hepatol* 2020; **18**: 2846-2847 [PMID: 32407783 DOI: 10.1016/j.cgh.2020.04.043]

38 **Ulrich H**, Pillat MM. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. *Stem Cell Rev Rep* 2020; **16**: 434-440 [PMID: 32307653 DOI: 10.1007/s12015-020-09976-7]

39 **Wang K**, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, Wei D, Zhang Y, Sun XX, Gong L, Yang X, He L, Zhang L, Yang Z, Geng JJ, Chen R, Zhang H, Wang B, Zhu YM, Nan G, Jiang JL, Li L, Wu J, Lin P, Huang W, Xie L, Zheng ZH, Zhang K, Miao JL, Cui HY, Huang M, Zhang J, Fu L, Yang XM, Zhao Z, Sun S, Gu H, Wang Z, Wang CF, Lu Y, Liu YY, Wang QY, Bian H, Zhu P, Chen ZN. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct Target Ther* 2020; **5**: 283 [PMID: 33277466 DOI: 10.1038/s41392-020-00426-x]

40 **Kondo Y**, Larabee JL, Gao L, Shi H, Shao B, Hoover CM, McDaniel JM, Ho YC, Silasi-Mansat R, Archer-Hartmann SA, Azadi P, Srinivasan RS, Rezaie AR, Borczuk A, Laurence JC, Lupu F, Ahamed J, McEver RP, Papin JF, Yu Z, Xia L. L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. *JCI Insight* 2021; **6** [PMID: 34291736 DOI: 10.1172/jci.insight.148999]

41 **Mao R**, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; **5**: 667-678 [PMID: 32405603 DOI: 10.1016/S2468-1253(20)30126-6]

42 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

43 **Nayagam JS**, Jeyaraj R, Mitchell T, Walder DP, Al-Agil M, Shek A, Barker R, Teo J, Maharaj R, Agarwal K, Vlachos S, Joshi D, McPhail MJ. Patterns and prediction of liver injury with persistent cholestasis in survivors of severe SARS-CoV-2 infection. *J Infect* 2021; **82**: e11-e13 [PMID: 33826926 DOI: 10.1016/j.jinf.2021.03.029]

44 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: 32283325 DOI: 10.1016/j.cgh.2020.04.002]

45 **Yip TC**, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, Tse YK, Hui DS, Chan HL, Wong GL. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. *Gut* 2021; **70**: 733-742 [PMID: 32641471 DOI: 10.1136/gutjnl-2020-321726]

46 **Kumar-M P**, Mishra S, Jha DK, Shukla J, Choudhury A, Mohindra R, Mandavdhare HS, Dutta U, Sharma V. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. *Hepatol Int* 2020; **14**: 711-722 [PMID: 32623633 DOI: 10.1007/s12072-020-10071-9]

47 **Foley CE**, Mulvey C, Boylan M, Reidy N, Reidy P, Moynan D, Worrall A, Curley G, Boland K, de Barra E, Ryan JD. Liver injury, hypoalbuminaemia and severe SARS-CoV-2 infection. *Gut* 2022; **71**: 225-226 [PMID: 34083385 DOI: 10.1136/gutjnl-2021-324570]

48 **Huang W**, Li C, Wang Z, Wang H, Zhou N, Jiang J, Ni L, Zhang XA, Wang DW. Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. *Sci China Life Sci* 2020; **63**: 1678-1687 [PMID: 32567003 DOI: 10.1007/s11427-020-1733-4]

49 **Gholizadeh P**, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K, Esposito S, Khodadadi E, Yousefi M, Samadi Kafil H. Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19). *J Inflamm Res* 2020; **13**: 285-292 [PMID: 32669866 DOI: 10.2147/JIR.S257078]

50 **Piano S**, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG, Framba V, Cerruti L, Mantovani A, Martini A, Luchetti MM, Serra R, Cattelan A, Vettor R, Angeli P; COVID-LIVER study group. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. *Liver Int* 2020; **40**: 2394-2406 [PMID: 32526083 DOI: 10.1111/Liv.14565]

51 **Gomi K**, Ito T, Yamaguchi F, Kamio Y, Sato Y, Mori H, Endo K, Abe T, Sakakura S, Kobayashi K, Shimada K, Noda J, Hibiki T, Ohta S, Sagara H, Tanaka A, Jinno M, Yamawaki M, Nishimoto F, Inoue K, Nagahama M. Clinical features and mechanism of liver injury in patients with mild or moderate coronavirus disease 2019. *JGH Open* 2021; **5**: 888-895 [PMID: 34386596 DOI: 10.1002/jgh3.12599]

52 **Kumar D**, Srivastava S, Rajnikant T, Dawra S, Tevatia MS, Mukherjee R. Liver function tests in COVID 19: A retrospective record-based study from a tertiary care centre in urban Maharashtra, India. *Med J Armed Forces India* 2022 [PMID: 35582519 DOI: 10.1016/j.mjafi.2022.02.010]

53 **Kulkarni AV**, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, Talukdar R, Sharma M, Qi X, Rao PN, Reddy DN. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther* 2020; **52**: 584-599 [PMID: 32638436 DOI: 10.1111/apt.15916]

54 **Chew M**, Tang Z, Radcliffe C, Caruana D, Doilicho N, Ciarleglio MM, Deng Y, Garcia-Tsao G. Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death. *Clin Gastroenterol Hepatol* 2021; **19**: 2182-2191.e7 [PMID: 34004326 DOI: 10.1016/j.cgh.2021.05.022]

55 **Lagana SM**, Kudose S, Iuga AC, Lee MJ, Fazlollahi L, Remotti HE, Del Portillo A, De Michele S, de Gonzalez AK, Saqi A, Khairallah P, Chong AM, Park H, Uhlemann AC, Lefkowitch JH, Verna EC. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. *Mod Pathol* 2020; **33**: 2147-2155 [PMID: 32792598 DOI: 10.1038/s41379-020-00649-x]

56 **Saviano A**, Baumert TF. Unraveling the role of liver sinusoidal endothelial cells in COVID-19 Liver injury. *J Hepatol* 2021; **75**: 503-505 [PMID: 34274367 DOI: 10.1016/j.jhep.2021.07.008]

57 **Lei P**, Zhang L, Han P, Zheng C, Tong Q, Shang H, Yang F, Hu Y, Li X, Song Y. Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury. *Hepatol Int* 2020; **14**: 733-742 [PMID: 32886333 DOI: 10.1007/s12072-020-10087-1]

58 **Del Nonno F**, Nardacci R, Colombo D, Visco-Comandini U, Cicalini S, Antinori A, Marchioni L, D'Offizi G, Piacentini M, Falasca L. Hepatic Failure in COVID-19: Is Iron Overload the Dangerous Trigger? *Cells* 2021; **10** [PMID: 34064487 DOI: 10.3390/cells10051103]

59 **Sonzogni A**, Previtali G, Seghezzi M, Grazia Alessio M, Gianatti A, Licini L, Morotti D, Zerbi P, Carsana L, Rossi R, Lauri E, Pellegrinelli A, Nebuloni M. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. *Liver Int* 2020; **40**: 2110-2116 [PMID: 32654359 DOI: 10.1111/Liv.14601]

60 **de Jesus RP**, de Carvalho JF, de Oliveira LPM, Cunha CM, Alves TCHS, Vieira STB, Figueiredo VM, Bueno AA. Metabolic and nutritional triggers associated with increased risk of liver complications in SARS-CoV-2. *World J Hepatol* 2022; **14**: 80-97 [PMID: 35126841 DOI: 10.4254/wjh.v14.i1.80]

61 **Guo W**, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev* 2020: e3319 [PMID: 32233013 DOI: 10.1002/dmrr.3319]

62 **Merad M**, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. *Science* 2022; **375**: 1122-1127 [PMID: 35271343 DOI: 10.1126/science.abm8108]

63 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

64 **Lu X**, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. *N Engl J Med* 2020; **382**: 1663-1665 [PMID: 32187458 DOI: 10.1056/NEJMc2005073]

65 **Perez A**, Cantor A, Rudolph B, Miller J, Kogan-Liberman D, Gao Q, Da Silva B, Margolis KG, Ovchinsky N, Martinez M. Liver involvement in children with SARS-COV-2 infection: Two distinct clinical phenotypes caused by the same virus. *Liver Int* 2021; **41**: 2068-2075 [PMID: 33826804 DOI: 10.1111/Liv.14887]

66 **Li Y**, Xu Q, Ma L, Wu D, Gao J, Chen G, Li H. Systematic profiling of ACE2 expression in diverse physiological and pathological conditions for COVID-19/SARS-CoV-2. *J Cell Mol Med* 2020; **24**: 9478-9482 [PMID: 32639084 DOI: 10.1111/jcmm.15607]

67 **Bahardoust M**, Heiat M, Khodabandeh M, Karbasi A, Bagheri-Hosseinabadi Z, Ataee MH, Seidalian N, Babazadeh A, Agah S, Abyazi MA. Predictors for the severe coronavirus disease 2019 (COVID-19) infection in patients with underlying liver disease: a retrospective analytical study in Iran. *Sci Rep* 2021; **11**: 3066 [PMID: 33542426 DOI: 10.1038/s41598-021-82721-3]

68 **Zhang H**, Liao YS, Gong J, Liu J, Zhang H. Clinical characteristics and risk factors for liver injury in COVID-19 patients in Wuhan. *World J Gastroenterol* 2020; **26**: 4694-4702 [PMID: 32884226 DOI: 10.3748/wjg.v26.i31.4694]

69 **Yang J**, Ma Z, Lei Y. A meta-analysis of the association between obesity and COVID-19. *Epidemiol Infect* 2020; **149**: e11 [PMID: 33349290 DOI: 10.1017/S0950268820003027]

70 **Wang Q**, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GJ, Xiong HF, Fan Y, Cao Y, Ding R, Wang JJ, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. *Mil Med Res* 2020; **7**: 28 [PMID: 32507110 DOI: 10.1186/s40779-020-00256-6]

71 **Krishnan A**, Prichett L, Tao X, Alqahtani SA, Hamilton JP, Mezey E, Strauss AT, Kim A, Potter JJ, Chen PH, Woreta TA. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. *World J Gastroenterol* 2022; **28**: 570-587 [PMID: 35316959 DOI: 10.3748/wjg.v28.i5.570]

72 **Fraser J**, Mousley J, Testro A, Smibert OC, Koshy AN. Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis. *Transplant Proc* 2020; **52**: 2676-2683 [PMID: 32891405 DOI: 10.1016/j.transproceed.2020.07.012]

73 **Zhang C**, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; **5**: 428-430 [PMID: 32145190 DOI: 10.1016/S2468-1253(20)30057-1]

74 **Lin J**, Bao B, Khurram NA, Halsey K, Choi JW, Wang L, Tran TML, Liao WH, Feldman MD, Zhang PJ, Wu J, Bai HX. Chronic liver disease not a significant comorbid condition for COVID-19. *Sci Rep* 2021; **11**: 11734 [PMID: 34083670 DOI: 10.1038/s41598-021-91238-8]

75 **Su F**. COVID-19 and Cirrhosis: A Combination We Must Strive to Prevent. *Gastroenterology* 2021; **161**: 1371-1373 [PMID: 34453892 DOI: 10.1053/j.gastro.2021.08.037]

76 **Iavarone M**, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Viganò M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Lucà M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol* 2020; **73**: 1063-1071 [PMID: 32526252 DOI: 10.1016/j.jhep.2020.06.001]

77 **Marjot T**, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, García-Juárez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Mercer C, Perumalswami PV, Avitabile E, Qi X, Su F, Ufere NN, Wong YJ, Zheng MH, Barnes E, Barritt AS 4th, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. *J Hepatol* 2021; **74**: 567-577 [PMID: 33035628 DOI: 10.1016/j.jhep.2020.09.024]

78 **Zou X**, Fang M, Li S, Wu L, Gao B, Gao H, Ran X, Bian Y, Li R, ShanshanYu, Ling J, Li D, Tian D, Huang J. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. *Clin Gastroenterol Hepatol* 2021; **19**: 597-603 [PMID: 32553907 DOI: 10.1016/j.cgh.2020.06.017]

79 **Wang J**, Lu Z, Jin M, Wang Y, Tian K, Xiao J, Cai Y, Wang Y, Zhang X, Chen T, Yao Z, Yang C, Deng R, Zhong Q, Deng X, Chen X, Yang XP, Wei G, Wang Z, Tian J, Chen XP. Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center retrospective cohort study. *Front Med* 2022; **16**: 111-125 [PMID: 34387851 DOI: 10.1007/s11684-021-0854-5]

80 **Lin Y**, Yuan J, Long Q, Hu J, Deng H, Zhao Z, Chen J, Lu M, Huang A. Patients with SARS-CoV-2 and HBV co-infection are at risk of greater liver injury. *Genes Dis* 2021; **8**: 484-492 [PMID: 33225036 DOI: 10.1016/j.gendis.2020.11.005]

81 **Singh A**, Premkumar M, Singh V. Liver injury in COVID-19 - The culprit may not be COVID-19!. *J Hepatol* 2021; **75**: 739-740 [PMID: 33753154 DOI: 10.1016/j.jhep.2021.03.010]

82 **Chen L**, Huang S, Yang J, Cheng X, Shang Z, Lu H, Cheng J. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. *J Viral Hepat* 2020; **27**: 1504-1507 [PMID: 32668494 DOI: 10.1111/jvh.13362]

83 **Xiang TD**, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. *World J Gastroenterol* 2021; **27**: 782-793 [PMID: 33727770 DOI: 10.3748/wjg.v27.i9.782]

84 **Dongiovanni P**, Meroni M, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. *Expert Rev Gastroenterol Hepatol* 2020; **14**: 867-872 [PMID: 32705906 DOI: 10.1080/17474124.2020.1801417]

85 **Singh MK**, Mobeen A, Chandra A, Joshi S, Ramachandran S. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? *Comput Biol Med* 2021; **130**: 104219 [PMID: 33486379 DOI: 10.1016/j.compbiomed.2021.104219]

86 **Xu L**, Liu J, Lu M, Yang D, Zheng X. Author response to Letter to the Editor: Potential implications of COVID-19 in non-alcoholic fatty liver disease. *Liver Int* 2020; **40**: 2569-2570 [PMID: 32558065 DOI: 10.1111/Liv.14564]

87 **Váncsa S**, Hegyi PJ, Zádori N, Szakó L, Vörhendi N, Ocskay K, Földi M, Dembrovszky F, Dömötör ZR, Jánosi K, Rakonczay Z Jr, Hartmann P, Horváth T, Erőss B, Kiss S, Szakács Z, Németh D, Hegyi P, Pár G. Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review. *Front Med (Lausanne)* 2020; **7**: 572115 [PMID: 33282888 DOI: 10.3389/fmed.2020.572115]

88 **Zhou YJ**, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. *J Hepatol* 2020; **73**: 719-721 [PMID: 32348790 DOI: 10.1016/j.jhep.2020.04.027]

89 **Tripon S**, Bilbault P, Fabacher T, Lefebvre N, Lescuyer S, Andres E, Schmitt E, Garnier-KepKA S, Borgne PL, Muller J, Merdji H, Chaffraix F, Mutter D, Baumert TF, Meziani F, Doffoel M. Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19. *Clin Res Hepatol Gastroenterol* 2022; **46**: 101894 [PMID: 35227956 DOI: 10.1016/j.clinre.2022.101894]

90 **Hashemi N**, Viveiros K, Redd WD, Zhou JC, McCarty TR, Bazarbashi AN, Hathorn KE, Wong D, Njie C, Shen L, Chan WW. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience. *Liver Int* 2020; **40**: 2515-2521 [PMID: 32585065 DOI: 10.1111/Liv.14583]

91 **Gao F**, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Chen YP, George J, Zheng MH. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. *J Gastroenterol Hepatol* 2021; **36**: 204-207 [PMID: 32436622 DOI: 10.1111/jgh.15112]

92 **Cholankeril G**, Goli K, Rana A, Hernaez R, Podboy A, Jalal P, Da BL, Satapathy SK, Kim D, Ahmed A, Goss J, Kanwal F. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. *Hepatology* 2021; **74**: 3316-3329 [PMID: 34310738 DOI: 10.1002/hep.32067]

93 **Deutsch-Link S**, Jiang Y, Peery AF, Barritt AS, Bataller R, Moon AM. Alcohol-Associated Liver Disease Mortality Increased From 2017 to 2020 and Accelerated During the COVID-19 Pandemic. *Clin Gastroenterol Hepatol* 2022; **20**: 2142-2144.e2 [PMID: 35314353 DOI: 10.1016/j.cgh.2022.03.017]

94 **Kim D**, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. *Clin Gastroenterol Hepatol* 2021; **19**: 1469-1479.e19 [PMID: 32950749 DOI: 10.1016/j.cgh.2020.09.027]

95 **Moon AM**, Curtis B, Mandrekar P, Singal AK, Verna EC, Fix OK. Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing Investigation. *Hepatol Commun* 2021; **5**: 1616-1621 [PMID: 34510833 DOI: 10.1002/hep4.1747]

96 **Qin J**, Wang H, Qin X, Zhang P, Zhu L, Cai J, Yuan Y, Li H. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient. *Hepatology* 2020; **72**: 1491-1493 [PMID: 32220017 DOI: 10.1002/hep.31257]

97 **Colmenero J**, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, Nuño J, Gastaca M, Bustamante-Schneider J, Cachero A, Lladó L, Caballero A, Fernández-Yunquera A, Loinaz C, Fernández I, Fondevila C, Navasa M, Iñarrairaegui M, Castells L, Pascual S, Ramírez P, Vinaixa C, González-Dieguez ML, González-Grande R, Hierro L, Nogueras F, Otero A, Álamo JM, Blanco-Fernández G, Fábrega E, García-Pajares F, Montero JL, Tomé S, De la Rosa G, Pons JA. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. *J Hepatol* 2021; **74**: 148-155 [PMID: 32750442 DOI: 10.1016/j.jhep.2020.07.040]

98 **Hundt MA**, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. *Hepatology* 2020; **72**: 1169-1176 [PMID: 32725890 DOI: 10.1002/hep.31487]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest for this work.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 12, 2022

**First decision:** October 19, 2022

**Article in press:**

**Specialty type:** Virology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Cojocariu C, Romania; Subhani M, United Kingdom **S-Editor:** Chen YL **L-Editor:** Wang TQ **P-Editor:** Chen YL

**Figure Legends**



**Figure 1 Mechanisms of liver injury caused by SARS-CoV-2.** The mechanisms include direct hepatoxicity (severe acute respiratory syndrome coronavirus 2 affects cholangiocytes or hepatocytes) or indirect hepatic injury (drug-induced liver injury, excessive systemic inflammation and cytokine storm, and deterioration of pre-existing liver disease). SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; ACE2: Angiotensin-converting enzyme 2; TMPRSS2: Transmembrane serine protease 2.



**Figure 2 Possible pathways of SARS-CoV-2 entering into the liver.** A: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) receptors by its S protein. Direct SARS-CoV-2 infection targeted to hepatocytes or billiary epithelial cells results in hepatocyte injury or bile duct injury; B and C: CD147 (B) and L-SIGN (C) may be alternative receptors for SARS-CoV-2 entry into the liver; D: Antibody dependent enhancement is a pathway which can enhance interaction of virus-based antibody and the CR and/or FC receptor complements further making virus easily entry and infection. ACE2: Angiotensin-converting enzyme 2; TMPRSS2: Transmembrane serine protease 2; LSECs: Liver sinusoidal endothelial cells; BECs: Biliary epithelial cells.

**Table 1 Abnormal liver function with existing liver disease and effects of COVID-19**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **No. of patients included** | **No. of patients with preexisting liver disease** | **Liver function markers** | **Impact on disease** |
| Cirrhosis | | | | |
| Iavarone *et al*[76], 2020 | 399 | 50 | Bilirubin and ALT significantly increased, while albumin significantly decreased | Elevated transaminases may have an adverse impact on the process of cirrhosis and the 30-d mortality rate was higher in those patients who had impaired liver function |
| Marjot *et al*[77], 2021 | 745 | 386 | - | SARS-CoV-2 infection in patients with cirrhosis appears to be associated with high rates of acute hepatic decompensation (46%) and patients would have a 2-fold increased rate of mortality |
| Hepatitis B | | | | |
| Zou *et al*[78], 2021 | 105 | 105 | Elevated levels of ALT (22, 20.95%), AST (29, 27.62%), total bilirubin (7, 6.67%), GST (7, 6.67%), and ALP (1, 0.95%) | Liver injury in patients with SARS-CoV-2 and chronic HBV co-infection was associated with disease severity |
| Chen *et al*[82], 2020 | 376 | 20 | No significant increase | Coinfection with SARS-CoV-2 and HBV slightly affected liver function and had no effect on COVID-19 outcomes |
| MAFLD | | | | |
| Zhou *et al*[88], 2020 | 327 | 93 | - | Younger COVID-19 patients (aged < 60 years) with MAFLD have a more than 2-fold higher prevalence of severe COVID-19 while MAFLD in older patients appears to have no relation to the severity of the disease |
| Tripon *et al*[89], 2022 | 719 | 445 | - | SARS-CoV-2-induced cytokine storm can be enhanced in patients with a preexisting liver disease like NAFLD |
| ALD | | | | |
| Kim *et al*[94], 2021 | 367 | 94 | - | Patients with ALD were at higher risk of contracting COVID-19 due to their immune system dysregulation and SARS-CoV-2-induced cytokine storm may exacerbate inflammation in ALD patients |
| Liver transplant | | | | |
| Fraser *et al*[72], 2020 | 223 | 223 | - | In liver transplant recipients with COVID-19, 77.7% required hospitalization, 36% experienced more severe disease, and the mortality rate observed in the cohort was 19.3% |
| Colmenero *et al*[97], 2021 | 111 | 111 | - | In liver transplant patients, chronic immune-suppression increases the risk of developing COVID-19 but it could reduce disease severity and the mortality |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GST: Gamma-glutamyl transpeptidase; MAFLD: Metabolic dysfunction-associated fatty liver disease; ALD: Alcoholic liver disease.